Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
DMNQ (HB3876)
Description:Cell-permeable, redox cycling quinone. Induces ROS generation.
Purity:>99%
- Description:
Effective agonist for muscarinic-based DREADDs in vitro and in vivo. Non-CNO chemogenetic actuator. Brain penetrant. Water soluble.
Purity:>98%
DREADD agonist 21 (Compound 21) (HB4888)
Description:Effective agonist for muscarinic-based DREADDs in vitro and in vivo. Non-CNO chemogenetic actuator. Brain penetrant.
Purity:>98%
DY131 (HB2491)
Description:Novel selective estrogen-related receptor ERRβ and ERRγ agonist
Purity:>99%
1-EBIO (HB1045)
Description:Epithelial KCa channel activator. Promotes ESC differentiation into cardiomyocytes.
Purity:>98%
EC 23 (HB2592)
Description:Synthetic retinoid. Induces neural differentiation of hESCs.
Purity:>99%